Cost-effectiveness acceptability curves comparing treating all untreated hypertensive adults (blue) with treating only untreated CVD patients and adults with stage 2 hypertension b... by Dongfeng Gu (216367)

Subjects:

Keywords and their explanations. by Emmanuel A. Odame (21369250)

Subjects:

Effectiveness and cost-effectiveness of implementing different BP control guidelines in untreated Chinese adults aged 35–84 y with hypertension, averaged from the projections for 2... by Dongfeng Gu (216367)

Subjects:

Inclusion and exclusion criteria for systematic review. by Warda Javed (15389332)

Subjects:

Outline of the Vaccine Champions program in Tonga. by Yasmin Mohamed (4032353)

Subjects:

Community attendees’ support for vaccines after attending a Vaccine Champion information session. by Yasmin Mohamed (4032353)

Subjects:

Theoretical framework for analysing driving and inhibiting factors in stunting reduction acceleration program in West Sumatra in 2021. by Syafrawati Syafrawati (14992310)

Subjects:

Overview of themes across four layers of influence. by Nyo Yamonn (19832257)

Subjects:

Data collection methods and outcomes for the Vaccine Champions program evaluation in Tonga. by Yasmin Mohamed (4032353)

Subjects:

Summary of identified social protection programs^b'*'. by Warda Javed (15389332)

Subjects:

Summary of reviewed literature. by Warda Javed (15389332)

Subjects:

Key demographic and socioeconomic characteristics of Norfolk City, Virginia [38]. by Valerie Michel (14315088)

Subjects:

Characteristics of Traditional Medicare, Medicare Advantage and non-Medicare Patients Received Lower Extremity Joint Replacement in Treatment and Control MSAs in California from 20... by Narae Kim (5809232)

Subjects:

Summary of five themes inhibiting social protection programs from realizing their full potential in reaching the poor. by Warda Javed (15389332)

Subjects:

Definitions for social equity provided by the interviewees by sector. by Valerie Michel (14315088)

Subjects:

Change in home discharge rates of hospitalizations in treatment relative to control MSAs in California from 2014 to 2017 (N = 312,914). by Narae Kim (5809232)

Subjects:

Participants’ characteristics. by Nyo Yamonn (19832257)

Subjects:

Driving and inhibiting factors of stunting reduction programs. by Syafrawati Syafrawati (14992310)

Subjects:

Characteristics of Vaccine Champions (N = 27). by Yasmin Mohamed (4032353)

Subjects:

Community attendees’ intention to vaccinate their child against HPV before and after a Vaccine Champion information session. by Yasmin Mohamed (4032353)

Subjects: